Trial Profile
To assess the efficacy of apatinib in first, second, third, fourth and fifth lines of treatment to patients with advanced/metastatic Non-Small-Cell-Lung-Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer